Announcements Trials
Browse Landscape

Phase

Phase 2 19Phase 1 7Phase 1/2 3Phase NA 1Phase 2/3 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 41Neoplasms, Plasma Cell 16Lymphoma, Non-Hodgkin 13Lymphoma 13Leukemia, Myeloid, Acute 13Leukemia 13Myelodysplastic Syndromes 11Hodgkin Disease 10Lymphoma, Mantle-Cell 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Follicular 7Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large B-Cell, Diffuse 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Congenital Abnormalities 4Neuroblastoma 3Melanoma 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Hematologic Neoplasms 3Graft vs Host Disease 3Burkitt Lymphoma 3Smoldering Multiple Myeloma 2Neoplasms 2Myeloproliferative Disorders 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Juvenile 2

Interventions

Cyclophosphamide 19fludarabine 18Tacrolimus 10Whole-Body Irradiation 9Mycophenolic Acid 8venetoclax 7fludarabine phosphate 7Sirolimus 7Azacitidine 7Mesna 5Dexamethasone 5Bortezomib 5Rituximab 4Methotrexate 4Busulfan 4daratumumab 3Stem Cell Transplantation 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3Lenalidomide 3Filgrastim 3Cytarabine 3Biopsy 3Alemtuzumab 3AP 1903 reagent 3pomalidomide 2merphos 2isatuximab 2ibrutinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Hematologic Neoplasms × Melphalan × Clear all
NCT05436418 2026-04-27

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
260 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01350258 2025-05-31

Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps

Thomas Jefferson University

Phase 1/2 Terminated
8 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT00202917 2014-05-29

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

University Hospital Tuebingen

Phase 1/2 Completed
61 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡